Cannabinoid receptor types 1 and 2 and peroxisome proliferator‐activated receptor‐α: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis

Miragliotta, Vincenzo; Ricci, Pier Luca; Albanese, Francesco; Pirone, Andrea; Tognotti, Danika; Abramo, Francesca

doi:10.1111/vde.12658

Cited by 18 publications

(27 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case by Ellis and Contino, dosing (0.5 mg/kg tapered to 0.33 mg/kg daily) was based on human recommendations and appears to be in-line with the lower end of dosing used in mouse and rat models of neuropathic pain. The ability of such low dosing of CBD to alleviate the clinical signs in this mare suggests high concentrations of cannabinoid receptors in the skin, as has been demonstrated in cats with hypersensitivity dermatitis (Miragliotta et al 2018). Therefore, further research into cannabinoid pharmacokinetics, pharmacodynamics and receptor distribution is warranted in horses, particularly given clinical reports of success in treating chronic pain states.…”

Section: Veterinary Research Of Cannabidiolmentioning

confidence: 79%

Cannabinoids in veterinary medicine: Is there evidence to support the trend?

Mercer

2019

Equine Veterinary Education

View full text Add to dashboard Cite

Section: Veterinary Research Of Cannabidiolmentioning

confidence: 79%

Cannabinoids in veterinary medicine: Is there evidence to support the trend?

Mercer

2019

Equine Veterinary Education

View full text Add to dashboard Cite

“…It is now clear that PEA is an endocannabinoid-related compound, sharing metabolic pathways and targets with the endocannabinoid system, which is now considered to play an integral role in maintaining body homeostasis [ 94 ]. Most notably, the heterogeneous family of canonical and putative cannabinoid receptors, i.e., PEA targets, are being extensively studied in companion animals and their distribution has been found in several body tissues [ 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 ]. Table 2 provides a summary of the main results.…”

Section: Pea Mechanism Of Action: a Multitarget Redundancymentioning

confidence: 99%

“…A glance over cannabinoid receptor distribution in dogs and cats[95][96][97][98][99][100][101][102][103][104][105][106][107][108][109].…”

mentioning

confidence: 99%

Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing

Gugliandolo

Peritore

Piras

et al. 2020

Veterinary Sciences

View full text Add to dashboard Cite

Virtually every cellular process is affected by diet and this represents the foundation of dietary management to a variety of small animal disorders. Special attention is currently being paid to a family of naturally occurring lipid amides acting through the so-called autacoid local injury antagonism, i.e., the ALIA mechanism. The parent molecule of ALIAmides, palmitoyl ethanolamide (PEA), has being known since the 1950s as a nutritional factor with protective properties. Since then, PEA has been isolated from a variety of plant and animal food sources and its proresolving function in the mammalian body has been increasingly investigated. The discovery of the close interconnection between ALIAmides and the endocannabinoid system has greatly stimulated research efforts in this field. The multitarget and highly redundant mechanisms through which PEA exerts prohomeostatic functions fully breaks with the classical pharmacology view of “one drug, one target, one disease”, opening a new era in the management of animals’ health, i.e., an according-to-nature biomodulation of body responses to different stimuli and injury. The present review focuses on the direct and indirect endocannabinoid receptor agonism by PEA and its analogues and also targets the main findings from experimental and clinical studies on ALIAmides in animal health and wellbeing.

show abstract

“…The antiallergic and anti‐inflammatory effects of PEA are known to be mediated through several receptors including the peroxisome proliferator‐activated receptor (PPAR)‐α and cannabinoid type‐1 and ‐2 receptors (CB1, CB2) . Interestingly, their expression is increased in the skin of cats with hypersensitivity dermatitis, suggesting that these receptors could represent new therapeutic targets for feline allergy …”

Section: Discussionmentioning

confidence: 99%

Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double‐blind, multicentre, randomized, placebo‐controlled study

Noli¹,

Valle²,

Miolo³

et al. 2019

Veterinary Dermatology

View full text Add to dashboard Cite

BackgroundFeline nonflea hypersensitivity dermatitis (NFHD) is a frequent cause of over‐grooming, scratching and skin lesions. Multimodal therapy often is necessary.Hypothesis/ObjectivesTo investigate the efficacy of ultramicronized palmitoylethanolamide (PEA‐um) in maintaining methylprednisolone‐induced remission in NFHD cats.AnimalsFifty‐seven NFHD cats with nonseasonal pruritus were enrolled originally, of which 25 completed all study requirements to be eligible for analysis.Methods and materialsCats were randomly assigned to PEA‐um (15 mg/kg per os, once daily; n = 29) or placebo (n = 28) while receiving a 28 day tapering methylprednisolone course. Cats responding favourably to methylprednisolone were then administered only PEA‐um (n = 21) or placebo (n = 23) for another eight weeks, followed by a four week long treatment‐free period. Cats were maintained in the study until relapse or study end, whichever came first. Primary outcome was time to relapse. Secondary outcomes were pruritus Visual Analog Scale (pVAS), SCORing Feline Allergic Dermatitis scale (SCORFAD) and owner Global Assessment Score (GAS).ResultsMean relapse time was 40.5 days (±7.8 SE) in PEA‐um treated cats (n = 13) and 22.2 days (±3.7 SE) for placebo (n = 12; P = 0.04). On Day 28, the severity of pruritus was lower in the PEA‐um treated cats compared to placebo (P = 0.03). Mean worsening of pruritus at the final study day was lower in the PEA‐um group compared to placebo (P = 0.04), whereas SCORFAD was not different between groups. Mean owner GAS at the final study day was better in the PEA‐um than the placebo‐treated group (P = 0.05).Conclusion and clinical importanceUltramicronized palmitoylethanolamide could represent an effective and safe option to delay relapse in NFHD cats.

show abstract

Cannabinoid receptor types 1 and 2 and peroxisome proliferator‐activated receptor‐α: distribution in the skin of clinically healthy cats and cats with hypersensitivity dermatitis

Abstract: Increased expression of cannabinoid receptors in the skin of cats with hypersensitivity dermatitis suggests an endogenous protective strategy and may support the use of natural cannabinoid receptor or PPAR-α agonists to treat feline hypersensitivity dermatitis.

Cited by 18 publications

References 41 publications

Cannabinoids in veterinary medicine: Is there evidence to support the trend?

Cannabinoids in veterinary medicine: Is there evidence to support the trend?

Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing

Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double‐blind, multicentre, randomized, placebo‐controlled study

Contact Info

Product

Resources

About